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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Pyrophosphate and 
vascular calcification
Vascular calcification is emerging as an 
important risk factor for cardiovascu-
lar mortality in end-stage renal disease 
(ESRD). Given the role that high phosphate 
levels in ESRD have in promoting calcifica-
tion, efforts to find agents that reverse or 
prevent calcification have received a high 
priority in research. As they report in this 
issue, O’Neill et al. used pyrophosphate as a 
potential therapeutic agent in experimental 
renal failure. They produced uremia in rats, 
fed them a high-phosphate diet, and then 
injected some of them with pyrophosphate. 
The incidence of calcification in the aorta 
remained the same, but their calcium con-
tent was drastically reduced by 70% with 
no effect on bone formation. These studies 
provide a new potential treatment for this 
problem. See page 512.
Biomarkers for  
acute kidney injury  
due to toxins
Although the diagnosis of acute renal fail-
ure is usually straightforward, the identifi-
cation of the cause is often challenging. In 
this issue, two papers attempt to provide 
new diagnostic tools that might differenti-
ate one cause from another. Ferreira et al. 
administered toxic doses of gentamicin or 
cisplatin to rats and examined their urine 
by two-dimensional gel electrophoresis, 
followed by sequencing of appropriate 
peptides. They found that the rats with 
gentamicin nephrotoxicity, but not those 
with cisplatin toxicity, had elevated levels 
of regenerating islet-derived protein III β 
(reg IIIb) and gelsolin in their urine. In 
another study, Kwon et al. followed up on 
the observation that not every animal given 
cisplatin develops renal failure. They used 
nuclear magnetic resonance spectroscopy 
to compare the excretion of metabolites 
in the urine of those that developed renal 
failure versus those that did not. A number 
of compounds were found that together 
were able to predict the sensitive animals. 
However, the application of these findings 
to the clinical setting has yet to occur. See 
page 518 and page 529.
Predicting the 
response to 
erythropoietin
Patients with ESRD who receive eryth-
ropoietin vary in their response, so it 
is important to identify those who will 
respond before treatment. Clinically, 
parameters of iron metabolism need to be 
examined first, because they may be the 
culprit in the response. However, there is 
still a need to distinguish the responders 
from the non-responders. As they report 
in this issue, Merchant et al. examined the 
sera of 35 patients by mass spectrometry 
and identified 91 peptides, 16 of which 
differed in abundance between good and 
poor responders. Three of these peptides, 
derived from oncostatin receptor β, were 
highly associated with poor response, 
although fibrinogen, factor XIII, comple-
ment factor 3, and cysteine/histidine-rich 
1 protein (CYHR1) were higher in good 
responders. Western blots confirmed and 
extended these studies. Hence, two new 
biomarkers are presented that should prove 
useful in difficult cases in which prediction 
of the response to erythropoietin is needed. 
See page 546.
